Affymax To Pay $6.5M To End Class Action Over Anemia Drug
Biopharmacuetical company Affymax Inc. has agreed to pay $6.5 million to settle a class action alleging it knowingly misled investors about the dangers of its drug Omontys, which was recalled in...To view the full article, register now.
Already a subscriber? Click here to view full article